No Detail Found!

Serum Cystatin C as An Early Diagnostic Biomarker of Diabetic Kidney Disease in Type 2 Diabetic Patients.

Author(s)
Ayesha Qamar Department of Pathology, Rawal Institute of Health Sciences (RIHS), Islamabad, Pakistan
Asma Hayat Department of Pathology, Army Medical College, Rawalpindi, Pakistan
Tariq Mahmood Ahmad Department of Pathology, Army Medical College, Rawalpindi, Pakistan
Alamgir Khan Department of Pathology, Army Medical College, Rawalpindi, Pakistan
Mohammad Najamul Hasnat Department of Pathology, Shaafi International Hospital, Islamabad, Pakistan
Sufyan Tahir Department of Pathology, Army Medical College, Rawalpindi, Department of Pathology, Rawal Institute of Health Sciences (RIHS), Islamabad,
Abstract
Objective: To determine the diagnostic accuracy and cut-off values of serum cystatin C as early diagnostic biomarker of diabetic kidney disease. Study Design: Cross-sectional analytical study. Place and Duration of Study: Department of Pathology, Army Medical College, Rawalpindi in collaboration with Endocrinology Department, Military Hospital (MH), Rawalpindi from November 2015 to November 2016. Methodology: One hundred and nineteen diagnosed patients of type 2 diabetes mellitus were enrolled in the study from the outpatient Endocrinology Department of the MH Rawalpindi. Fifty disease-free controls were also included. Fasting blood samples of the patients and controls were analysed for creatinine by Jaffé's kinetic method and estimated GFR was calculated using MDRD-based equation for GFR. Serum cystatin C was estimated by quantitative turbidimetric method. Results: Serum cystatin C was higher in the diabetic group (mean = 1.022 ±0.33 mg/dl) as compared to the control group (mean = 0.63 ±0.14 mg/dl). ROC curve analysis, keeping less than 60 ml/min/1.73 m2 GFR (CKD-MDRD based) as reference value of the stat variable/gold standard; revealed an area under the curve of 0.914 (95% CI 0.85-0.98) and at optimal sensitivity of 88.2% and specificity of 84.8% the established cut-off of serum cystatin C was 1.26 mg/L. Conclusion: Cystatin C is an accurate biomarker of diabetic kidney disease with good sensitivity and specificity.
Publication Details
Page(s) 288-291
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 4, Year: 2018

Request the full text from PASTIC

References
GuariguataL,WhitingD,HambletonI,BeagleyJ,LinnenkampU,ShawJ, 2014.Global estimates of diabetes prevalence for 2013 and projections for 2035,Diabetes Res Clin Pract 103 137 -49
TangSC,ChanGC,LaiKN, 2016.Recent advances in managing and understanding diabetic nephropathy,F1000Res 31 5 -
MacIsaacRJ,TsalamandrisC,PanagiotopoulosS,SmithTJ,McNeilKJ,JerumsG, 2004.Nonalbuminuric renal insufficiency in type 2 diabetes,Diabetes Care 27 195 -200
2015.,Index. Diabetes Care 38 S90 -3
PerroneRD,MadiasNE,LeveyAS, 1992.Serum creatinine as an index of renal function: new insights into old concepts,Clin Chem 38 1933 -53
LacquanitiA,DonatoV,PintaudiB,Di ViesteG,ChiricoV,BuemiA, 2013.Normoalbuminuric diabetic nephropathy: tubular damage and NGAL,Acta Diabetol 50 935 -42
AvinashS,SinghV,AgarwalA,ChatterjeeS,AryaV, 2015.Identification and stratification of diabetic kidney disease using serum cystatin C and serum creatinine based estimating equations in type 2 diabetes: A comparative analysis,J Assoc Physicians India 63 28 -
JavanmardiM,AzadiN-A,AminiS,AbdiM., 2015.Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran,J Res Med Sci 20 571 -
RossingP,HougaardP,ParvingHH, 2005.Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study,Kidney Int 68 1446 -50
MacIsaacRJ,EkinciEI,JerumsG, 2014.Markers of and risk factors for the development and progression of diabetic kidney disease,Am J Kidney Dis 63 S39 -62
KumarAA, 2015.Comparison of various formulas used to calculate eGFR in type 2 diabetes mellitus,Int J Health Sci Res 5 283 -9
MussapM,Dalla VestraM,FiorettoP,SallerA,VaragnoloM,NosadiniR, 2002.Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients,Kidney Int 61 1453 -61
ShemeshO,GolbetzH,KRIssJP,MyersBD, 1985.Limitations of creatinine as a filtration marker in glomerulopathic patients,Kidney Int 28 830 -8
CaramoriML,FiorettoP,MauerM, 2003.Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients an indicator of more advanced glomerular lesions,Diabetes 52 1036 -40
ChristenssonA,GrubbA,NilssonJ,NorrgrenK,SternerG,SundkvistG, 2004.Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy,J Intern Med 256 510 -8
GabrielIC,NishidaSK,KirsztajnGM, 2011.Serum cystatin C: a practical alternative for renal function evaluation?,J Brasileiro Nefrol 33 261 -7
FathimahM,AlicezahMK,ThevarajahM. Neutrophil, 2012.Gelatinase-Associated Lipocalin (NGAL): an early marker for diabetic nephropathy,Int J Diabetes Dev Ctries 32 19 -24
de CarvalhoJAM,TatschE,HausenBS,BollickYS,MorettoMB,DuarteT, 2016.Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes,Clin Biochem 49 232 -6
El-KafrawyNA,ShohaibAA,El-DeenSMK,El BarbaryH,SeleemAS, 2014.Evaluation of serum cystatin C as an indicator of early renal function decline in type 2 diabetes,Menoufia Med J 27 60 -
SinglaK,SodhiK,PandeyR,SinghJ,SharmaP., 2014.The utility of serum cystatin C in the diagnosis of early diabetic nephropathy,J Pharm Biomed Sci 4 84 -7
RaoGSN,AbayambigaiJ,SrutiE,SowmiyaK., 2014.Early prediction of nephropathy and cardiovascular diseases in Indian patients with type 2 diabetes mellitus,Int J Med Sci Public Health 3 1523 -7
SuzukiY,MatsushitaK,SeimiyaM,YoshidaT,SawabeY,OgawaM, 2012.Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes,Clin Chem Lab Med 50 1833 -9
0

Citations

0

Downloads

42

Views